MedPath

Tamsulosin

Generic Name
Tamsulosin
Brand Names
Flomax, Jalyn
Drug Type
Small Molecule
Chemical Formula
C20H28N2O5S
CAS Number
106133-20-4
Unique Ingredient Identifier
G3P28OML5I
Background

Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.

Tamsulosin was first approved by the FDA on April 15, 1997.

Indication

Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.

Associated Conditions
Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus
Associated Therapies
-

Treatment of Supine Hypertension in Autonomic Failure

First Posted Date
2005-09-22
Last Posted Date
2017-10-13
Lead Sponsor
Vanderbilt University
Target Recruit Count
152
Registration Number
NCT00223717
Locations
🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy

Not Applicable
Terminated
Conditions
Urolithiasis
Interventions
Drug: Flomax
Drug: Sugar pill
First Posted Date
2005-09-21
Last Posted Date
2013-10-28
Lead Sponsor
Emory University
Target Recruit Count
24
Registration Number
NCT00209131
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

Evaluation of Tamsulosin in the Treatment of Ureteral Stones

Phase 3
Completed
Conditions
Ureterolithiasis
Ureteral Calculi
Interventions
Drug: Tamsulosin
Drug: Placebo
First Posted Date
2005-09-09
Last Posted Date
2012-12-04
Lead Sponsor
Rennes University Hospital
Target Recruit Count
129
Registration Number
NCT00151567
Locations
🇫🇷

Hôpital de Redon, Redon, France

🇫🇷

Service d'Urologie- Hôpital du Val de Grâce, Paris, France

🇫🇷

Service d'Urologie- Hôpital Robert Debré, Reims, France

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath